 ASLAN Pharmaceuticals Nasdaq:ASLN, TPEx:6497, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that recruitment of new patients into its randomised, double-blind, placebo-controlled multiple 